Trials / Completed
CompletedNCT05774184
A Study of CDX-0159 in Patients With Eosinophilic Esophagitis
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults With Active Eosinophilic Esophagitis (The "EvolvE" Study)
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 86 (actual)
- Sponsor
- Celldex Therapeutics · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
Detailed description
The purpose of this study is to assess the efficacy and safety of barzolvolimab in adult Eosinophilic Esophagitis patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | barzolvolimab | subcutaneous administration |
| DRUG | Matching Placebo | subcutaneous administration |
Timeline
- Start date
- 2023-06-01
- Primary completion
- 2025-06-04
- Completion
- 2026-01-23
- First posted
- 2023-03-17
- Last updated
- 2026-01-30
Locations
45 sites across 8 countries: United States, Australia, Canada, Germany, Italy, Poland, Spain, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05774184. Inclusion in this directory is not an endorsement.